Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stomach Neoplasms | 15 | 2024 | 281 | 3.790 |
Why?
|
| Neuroendocrine Tumors | 8 | 2024 | 117 | 2.860 |
Why?
|
| Adenocarcinoma | 14 | 2022 | 1194 | 2.040 |
Why?
|
| Gastritis | 3 | 2023 | 36 | 1.840 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 667 | 1.650 |
Why?
|
| Biomarkers, Tumor | 9 | 2019 | 1543 | 1.350 |
Why?
|
| Immunohistochemistry | 9 | 2021 | 1796 | 1.070 |
Why?
|
| Gastric Mucosa | 4 | 2019 | 66 | 1.020 |
Why?
|
| Gastritis, Atrophic | 1 | 2023 | 4 | 0.920 |
Why?
|
| Adenoma | 3 | 2019 | 246 | 0.870 |
Why?
|
| Colorectal Neoplasms | 5 | 2024 | 981 | 0.800 |
Why?
|
| DNA Mutational Analysis | 2 | 2019 | 529 | 0.760 |
Why?
|
| Barrett Esophagus | 2 | 2021 | 93 | 0.750 |
Why?
|
| Helicobacter Infections | 1 | 2021 | 37 | 0.750 |
Why?
|
| Helicobacter pylori | 1 | 2021 | 37 | 0.750 |
Why?
|
| Plasma Cells | 1 | 2021 | 84 | 0.740 |
Why?
|
| Stomach | 1 | 2021 | 111 | 0.730 |
Why?
|
| Microsatellite Instability | 2 | 2019 | 49 | 0.700 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2022 | 575 | 0.660 |
Why?
|
| Colitis, Lymphocytic | 1 | 2018 | 4 | 0.620 |
Why?
|
| Antidiarrheals | 1 | 2018 | 14 | 0.620 |
Why?
|
| Metaplasia | 1 | 2018 | 37 | 0.610 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2017 | 4 | 0.610 |
Why?
|
| Carcinoma, Acinar Cell | 1 | 2017 | 12 | 0.610 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 481 | 0.600 |
Why?
|
| Receptor, ErbB-2 | 1 | 2019 | 245 | 0.600 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 273 | 0.590 |
Why?
|
| Mesalamine | 1 | 2018 | 88 | 0.580 |
Why?
|
| Carcinogenesis | 1 | 2019 | 211 | 0.570 |
Why?
|
| Early Detection of Cancer | 2 | 2020 | 415 | 0.570 |
Why?
|
| Steroids | 1 | 2018 | 174 | 0.560 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2020 | 2335 | 0.550 |
Why?
|
| Aged | 23 | 2024 | 19078 | 0.530 |
Why?
|
| Humans | 51 | 2024 | 89073 | 0.530 |
Why?
|
| Biopsy | 6 | 2024 | 1182 | 0.520 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 18 | 0.520 |
Why?
|
| Aged, 80 and over | 13 | 2024 | 6777 | 0.500 |
Why?
|
| Female | 34 | 2024 | 46014 | 0.490 |
Why?
|
| Middle Aged | 25 | 2024 | 25865 | 0.490 |
Why?
|
| Mutation | 3 | 2024 | 4132 | 0.490 |
Why?
|
| Adult | 25 | 2024 | 26508 | 0.460 |
Why?
|
| Male | 32 | 2024 | 42254 | 0.450 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 35 | 0.410 |
Why?
|
| Nevus | 1 | 2012 | 15 | 0.410 |
Why?
|
| Predictive Value of Tests | 4 | 2021 | 1715 | 0.410 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 142 | 0.390 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2019 | 412 | 0.390 |
Why?
|
| Endoscopic Mucosal Resection | 2 | 2022 | 27 | 0.380 |
Why?
|
| Precancerous Conditions | 1 | 2012 | 200 | 0.370 |
Why?
|
| Goblet Cells | 2 | 2022 | 20 | 0.360 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 161 | 0.360 |
Why?
|
| Leukemia, Lymphoid | 1 | 2010 | 72 | 0.360 |
Why?
|
| Inclusion Bodies | 1 | 2010 | 34 | 0.360 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 579 | 0.350 |
Why?
|
| Lung Neoplasms | 1 | 2022 | 2347 | 0.350 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 665 | 0.340 |
Why?
|
| Mastocytosis, Systemic | 1 | 2009 | 12 | 0.330 |
Why?
|
| Nerve Tissue Proteins | 1 | 2012 | 511 | 0.330 |
Why?
|
| Breast Diseases | 1 | 2009 | 100 | 0.310 |
Why?
|
| Esophageal Neoplasms | 3 | 2020 | 332 | 0.310 |
Why?
|
| Lymphocytes | 1 | 2010 | 471 | 0.300 |
Why?
|
| Melanoma | 1 | 2012 | 467 | 0.300 |
Why?
|
| Adolescent | 10 | 2021 | 9237 | 0.300 |
Why?
|
| Herpesvirus 4, Human | 2 | 2019 | 119 | 0.290 |
Why?
|
| Young Adult | 9 | 2021 | 6289 | 0.290 |
Why?
|
| Cysticercosis | 1 | 2007 | 2 | 0.290 |
Why?
|
| Submandibular Gland Diseases | 1 | 2007 | 9 | 0.290 |
Why?
|
| Cadherins | 2 | 2019 | 163 | 0.290 |
Why?
|
| Lip Neoplasms | 1 | 2006 | 8 | 0.280 |
Why?
|
| Salivary Glands, Minor | 1 | 2006 | 9 | 0.280 |
Why?
|
| Carcinoma | 2 | 2019 | 443 | 0.270 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2006 | 67 | 0.260 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 9 | 0.240 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 24 | 0.240 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 22 | 0.240 |
Why?
|
| Adenomatous Polyps | 1 | 2024 | 13 | 0.240 |
Why?
|
| Intestinal Mucosa | 2 | 2022 | 805 | 0.240 |
Why?
|
| Intestinal Neoplasms | 1 | 2024 | 64 | 0.230 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 122 | 0.230 |
Why?
|
| Exodeoxyribonucleases | 1 | 2023 | 17 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 967 | 0.220 |
Why?
|
| Biology | 1 | 2023 | 52 | 0.220 |
Why?
|
| Opportunistic Infections | 2 | 2022 | 60 | 0.220 |
Why?
|
| Lymphocytosis | 1 | 2022 | 12 | 0.210 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.210 |
Why?
|
| Reference Standards | 1 | 2022 | 144 | 0.210 |
Why?
|
| Mitotic Index | 1 | 2022 | 21 | 0.200 |
Why?
|
| Aberrant Crypt Foci | 1 | 2022 | 7 | 0.200 |
Why?
|
| Tissue Array Analysis | 2 | 2019 | 127 | 0.200 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 146 | 0.190 |
Why?
|
| Gastroscopy | 1 | 2021 | 25 | 0.190 |
Why?
|
| Colitis | 1 | 2024 | 244 | 0.190 |
Why?
|
| Neoplasm Grading | 2 | 2019 | 372 | 0.190 |
Why?
|
| Catheter Ablation | 1 | 2023 | 252 | 0.190 |
Why?
|
| Gastrointestinal Tract | 2 | 2021 | 191 | 0.190 |
Why?
|
| 5-Methylcytosine | 1 | 2022 | 117 | 0.190 |
Why?
|
| Pathologists | 1 | 2021 | 27 | 0.180 |
Why?
|
| Interferon Regulatory Factors | 1 | 2021 | 69 | 0.180 |
Why?
|
| Lifting | 1 | 2020 | 12 | 0.180 |
Why?
|
| Collagen | 2 | 2022 | 293 | 0.180 |
Why?
|
| Duodenal Neoplasms | 1 | 2019 | 19 | 0.170 |
Why?
|
| Republic of Korea | 1 | 2019 | 31 | 0.170 |
Why?
|
| Smad4 Protein | 1 | 2019 | 24 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2007 | 1096 | 0.170 |
Why?
|
| Actinomycosis | 1 | 2019 | 12 | 0.170 |
Why?
|
| Biomarkers | 2 | 2021 | 1755 | 0.170 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2019 | 11 | 0.170 |
Why?
|
| Disease Progression | 3 | 2018 | 1488 | 0.170 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 41 | 0.160 |
Why?
|
| Observer Variation | 1 | 2021 | 610 | 0.160 |
Why?
|
| In Situ Hybridization | 2 | 2017 | 313 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 20 | 0.160 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 55 | 0.160 |
Why?
|
| Appendicitis | 1 | 2019 | 64 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.160 |
Why?
|
| Retrospective Studies | 7 | 2023 | 9003 | 0.160 |
Why?
|
| Cervical Vertebrae | 1 | 2019 | 81 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 195 | 0.160 |
Why?
|
| Bismuth | 1 | 2018 | 8 | 0.160 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2752 | 0.150 |
Why?
|
| Carcinoid Tumor | 1 | 2018 | 45 | 0.150 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 164 | 0.150 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2018 | 24 | 0.150 |
Why?
|
| Salicylates | 1 | 2018 | 25 | 0.150 |
Why?
|
| Child, Preschool | 3 | 2021 | 3717 | 0.150 |
Why?
|
| Appendiceal Neoplasms | 1 | 2018 | 31 | 0.150 |
Why?
|
| Acinar Cells | 1 | 2017 | 7 | 0.150 |
Why?
|
| Antigens, CD | 1 | 2019 | 466 | 0.150 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 507 | 0.150 |
Why?
|
| Gene Amplification | 1 | 2018 | 134 | 0.150 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 1591 | 0.150 |
Why?
|
| Cetuximab | 1 | 2018 | 117 | 0.150 |
Why?
|
| Endoscopy, Digestive System | 1 | 2017 | 68 | 0.150 |
Why?
|
| Lung | 2 | 2022 | 1258 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2019 | 691 | 0.140 |
Why?
|
| Microscopy, Electron | 1 | 2017 | 510 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 134 | 0.140 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 754 | 0.140 |
Why?
|
| Camptothecin | 1 | 2018 | 193 | 0.140 |
Why?
|
| Cecum | 1 | 2016 | 69 | 0.140 |
Why?
|
| Terminology as Topic | 1 | 2018 | 221 | 0.140 |
Why?
|
| Anemia | 1 | 2017 | 129 | 0.140 |
Why?
|
| Phenotype | 2 | 2019 | 2439 | 0.140 |
Why?
|
| Child | 4 | 2021 | 7149 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 2015 | 19 | 0.130 |
Why?
|
| Polyps | 1 | 2015 | 29 | 0.130 |
Why?
|
| Colitis, Ulcerative | 1 | 2022 | 736 | 0.130 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 342 | 0.120 |
Why?
|
| Ultrasonography | 1 | 2017 | 711 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2023 | 8203 | 0.120 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 573 | 0.110 |
Why?
|
| Population | 1 | 2013 | 35 | 0.110 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2013 | 44 | 0.110 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2013 | 16 | 0.110 |
Why?
|
| Precision Medicine | 1 | 2017 | 410 | 0.110 |
Why?
|
| United States | 3 | 2024 | 6957 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2013 | 70 | 0.110 |
Why?
|
| Nestin | 1 | 2012 | 18 | 0.100 |
Why?
|
| Genomics | 1 | 2017 | 761 | 0.100 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2011 | 2 | 0.100 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 158 | 0.100 |
Why?
|
| Age Factors | 1 | 2016 | 1867 | 0.100 |
Why?
|
| Microbiota | 1 | 2016 | 398 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2019 | 2863 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 2552 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 576 | 0.090 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2010 | 5 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2013 | 373 | 0.090 |
Why?
|
| Mast Cells | 1 | 2009 | 94 | 0.080 |
Why?
|
| Leucovorin | 2 | 2020 | 224 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2009 | 81 | 0.080 |
Why?
|
| Bone Marrow | 1 | 2010 | 445 | 0.080 |
Why?
|
| Fever | 1 | 2008 | 128 | 0.070 |
Why?
|
| Wuchereria bancrofti | 1 | 2007 | 2 | 0.070 |
Why?
|
| Filariasis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lung Abscess | 1 | 2007 | 5 | 0.070 |
Why?
|
| Lymphatic Diseases | 1 | 2007 | 36 | 0.070 |
Why?
|
| Histiocytosis, Sinus | 1 | 2007 | 15 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2020 | 561 | 0.070 |
Why?
|
| Mammaplasty | 1 | 2009 | 109 | 0.070 |
Why?
|
| Submandibular Gland Neoplasms | 1 | 2007 | 7 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2013 | 3000 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 285 | 0.070 |
Why?
|
| Keratins | 1 | 2006 | 63 | 0.070 |
Why?
|
| Chronic Disease | 1 | 2010 | 948 | 0.070 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2007 | 58 | 0.070 |
Why?
|
| Granuloma | 2 | 2019 | 65 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2399 | 0.060 |
Why?
|
| Octreotide | 1 | 2024 | 23 | 0.060 |
Why?
|
| Prognosis | 1 | 2012 | 3773 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 2553 | 0.060 |
Why?
|
| Microwaves | 1 | 2023 | 36 | 0.060 |
Why?
|
| Colonic Polyps | 1 | 2024 | 132 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 11 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 37 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2022 | 39 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2023 | 170 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 76 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 91 | 0.050 |
Why?
|
| Atrophy | 1 | 2022 | 119 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Colonoscopy | 1 | 2024 | 279 | 0.050 |
Why?
|
| Loss of Heterozygosity | 1 | 2022 | 86 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2022 | 92 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 152 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 77 | 0.050 |
Why?
|
| India | 2 | 2013 | 123 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2021 | 43 | 0.050 |
Why?
|
| DNA Copy Number Variations | 1 | 2022 | 177 | 0.050 |
Why?
|
| Colon | 1 | 2024 | 509 | 0.050 |
Why?
|
| Hydrogels | 1 | 2021 | 86 | 0.050 |
Why?
|
| Injections | 1 | 2020 | 116 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 921 | 0.040 |
Why?
|
| Mentors | 1 | 2021 | 85 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 362 | 0.040 |
Why?
|
| Actinomyces | 1 | 2019 | 5 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2021 | 179 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2019 | 27 | 0.040 |
Why?
|
| Duodenum | 1 | 2019 | 103 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 111 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 69 | 0.040 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 58 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 336 | 0.040 |
Why?
|
| Organoplatinum Compounds | 1 | 2018 | 97 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2024 | 3657 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 348 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2007 | 105 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 58 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 128 | 0.030 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 447 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1214 | 0.030 |
Why?
|
| Mice | 2 | 2021 | 11742 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1848 | 0.030 |
Why?
|
| Endosonography | 1 | 2015 | 98 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 500 | 0.030 |
Why?
|
| Homeostasis | 1 | 2016 | 413 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 866 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 220 | 0.030 |
Why?
|
| Cytochrome P-450 CYP2C8 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2015 | 502 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 5466 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2013 | 147 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2018 | 2001 | 0.030 |
Why?
|
| Axilla | 1 | 2013 | 104 | 0.030 |
Why?
|
| Animals | 3 | 2021 | 27324 | 0.030 |
Why?
|
| Mastectomy, Segmental | 1 | 2013 | 101 | 0.030 |
Why?
|
| Schwann Cells | 1 | 2011 | 34 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2018 | 1363 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 685 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 1592 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 2011 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2011 | 151 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2011 | 160 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 2010 | 130 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 3211 | 0.020 |
Why?
|
| Microscopy | 1 | 2010 | 87 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2010 | 118 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4273 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1710 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2013 | 548 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 15 | 0.020 |
Why?
|
| Bone Marrow Examination | 1 | 2008 | 47 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 1108 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2412 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1975 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 233 | 0.020 |
Why?
|
| Chin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2011 | 688 | 0.020 |
Why?
|